PUBLICACIONES

2018

Women have enhanced bone loss associated with phosphaturia and CD4 cell restoration during initial antiretroviral therapy.
Enlace: https://www.ncbi.nlm.nih.gov/pubmed/30134291
Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS).
Enlace: https://academic.oup.com/ofid/article/5/6/ofy103/5032747
High Baseline Anal Human Papillomavirus and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Individuals Older Than 26 Years: ACTG 5298.
Enlace: https://www.ncbi.nlm.nih.gov/pubmed/29528986
ACTG A5353: a pilot study of dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA < 500,000 copies/mL.
Enlace: https://academic.oup.com/cid/article/66/11/1689/4743559
Desde Puerto Rico podrían desarrollar nanopartículas ante nueva era clínica contra el VIH.
Enlace: https://medicinaysaludpublica.com/desde-puerto-rico-podrian-desarrollar-nanoparticulas-ante-nueva-era-clinica-contra-el-vih/-with

2017

Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults.
Enlace: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427981/
Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women A Phase 2 Randomized Trial.
Enlace: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667908/
Dr. Jorge Santana: A la caza de los virus que afectan a los puertorriqueños.
Enlace: https://medicinaysaludpublica.com/dr-jorge-santana-dedica-su-carrera-a-la-investigacion-contra-el-sida/

2016

Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305).
Enlace: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790146/
Se prolonga la vida de los pacientes de SIDA en Puerto Rico
Enlace: https://medicinaysaludpublica.com/se-prologa-la-vida-de-los-pacientes-de-sida-en-puerto-rico/

2015

HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial.
Enlace: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681296/
Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257
Enlace: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660025/
Less Bone Loss WithMaraviroc-Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.
Enlace: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560904/
Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1–Infected Adults Receiving Long-term Antiretroviral Therapy.
Enlace: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4721905/
Reductions in Plasma Cystatin C after Initiation of Antiretroviral Therapy are Associated with Reductions in Inflammation: ACTG A5224s.
Enlace: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445470/pdf/nihms657473.pdf

2014

Metabolic syndrome in relation to cardiorespiratory fitness, active and sedentary behavior in HIV+ Hispanics with and without lipodystrophy.
Enlace: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329015/pdf/nihms-657179.pdf
La resistenciabacteriana: enemigo de la salud pública. Revista puertorriqueña de Medicina y Salud Pública.
Enlace: https://medicinaysaludpublica.com/la-resistencia-bacteriana-enemigo-de-la-salud-publica-2/
Puerto Rico frente al SIDA. Revista puertorriqueña de Medicina y Salud Pública.
Enlace: https://medicinaysaludpublica.com/puerto-rico-frente-al-sida-entrevista-al-dr-jorge-santana-director-de-actu-e-investigador-principal/

2013

Nuevos avances en el tratamiento del paciente co-infectado con Hepatitis C y VIH.
Perspectivas e implicaciones clinicas para la estrategia de identificacion y tratamiento temprano.
Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.
Enlace: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549598/

2011

Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis.
Enlace: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3121543/
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
Enlace: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3173503/
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.
Enlace: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430716/

2010

Bone disease in HIV infection: a practical reviewand recommendations for HIV care providers.
Enlcae: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3105903/
Detection of KPC in Acinetobacter spp. in Puerto Rico. Antimicrob Agents Chemother.
Enlcae: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825984/pdf/0899-09.pdf
Prevalence of cardiometabolic risk factors in Hispanics living with HIV.
Enlcae: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071519/
Uridine supplementation in the treatment of HIV lipoatrophy: Results of ACTG 5229. http://doi.org/10.1097/QAD.0b013e32833ea9bc
ACTG 5197: A Placebo Controlled Trial of Immunization of HIV-1 Infected Persons with a Replication Deficient Ad5 Vaccine Expressing the HIV-1 Core Protein. http://doi.org/10.1086/655468
Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial.
http://doi.org/10.1086/651118
Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection.
Enlace: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018341/

2009

Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial.
Enlace: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2771688/
Fatal granulomatous meningoencephalitis associated to mycobacterium mucogenicum-like microorganism: a case report.
Enlace: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2909603/
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
Enlcae: https://www.nejm.org/doi/full/10.1056/NEJMoa0906768
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.
Enlace: https://www.ncbi.nlm.nih.gov/pubmed/19710593
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance.
Enlace: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2706549/

2007

Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple- nucleoside or efavirenz-containing regimens: ACTG A5166s.
Enlace: https://academic.oup.com/jid/article/195/8/1169/817058

2006

A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).
Enlace: https://academic.oup.com/jid/article-lookup/doi/10.1086/509508
Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing currenttherapy (ACTG A5118).
Enlace: https://www.ncbi.nlm.nih.gov/pubmed/16964830

2003

A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir.
Enlace: https://miami.pure.elsevier.com/en/publications/a-randomized-trial-of-nelfinavir-and-abacavir-in-combination-with